Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/phase-3-palopegteriparatide-results-show-sustained-benefits-2026a1000jyi?src=rss
Author :
Publish date : 2026-06-14 17:43:00
Copyright for syndicated content belongs to the linked Source.
